Abstract: A device for removing toxins from the blood of patients suffering from acute liver failure, acute-on-chronic liver failure and sepsis is provided. The toxin removal device disclosed herein comprises activated charcoal and at least one non-ionic resin for use in an extracorporeal circuit that minimizes electrolyte and protein depletion from the treated plasma. Also provided are associated methods for treating patients suffering from acute liver failure, acute-on-chronic liver failure and sepsis using the disclosed toxin removal device.

Abstract: The present invention relates to novel antimicrobial silver ion complex resinates. More particularly, the present invention contemplates silver ion complex resinate compositions comprising a silver-thiosulfate ion complex loaded onto an organic anion exchange resin. These silver thiosulfate ion complex resinate compositions are able to release stable antimicrobial silver ion complexes when placed in a saline environment. These antimicrobial silver-ion complex resinates are useful in the treatment and prevention of infections and diseases.

Abstract: The present invention provides a method of treating meconium aspiration syndrome, said method comprising administering to a subject in need of treatment a therapeutically effective amount of albumin. A further aspect of the invention relates to the use of albumin in the preparation of a medicament for treating meconium aspiration syndrome, and a pharmaceutical composition comprising albumin admixed with a pharmaceutically acceptable carrier, diluent or excipient.

Abstract: It is mentioned to provide drugs for ameliorating postcibal hyperglycemia, drugs for inhibiting an increase in blood glucose level and pharmaceutical compositions for preventing or treating diabetics each containing a pharmaceutically acceptable anion exchange resin typified by colestimide. Thus, it becomes possible to provide drugs clearly exhibiting an effect of inhibiting an increase in postcibal blood glucose level.

Abstract: Dental compositions comprising at least a polymerizable monomer and/or at least a polyaminoester that are prepared by reaction of bis- or polyacrylic esters and amines, pigments, organic and/or inorganic fillers, initiators and stabilizers.

Abstract: Matrices that support cell adhesion and growth are disclosed that deliver low heparin-binding affinity growth factor protein peptides in a controlled manner. These matrices comprise covalently or non-covalently bound heparin or heparin-like polymers, which serve to sequester the low heparin-binding affinity growth factor protein peptides within the matrix. The controlled release of some low heparin-binding affinity growth factor or peptides thereof occurs by degradation of some matrix component or dissociation of the low heparin-binding affinity growth factor protein peptides from the bound heparin. This differs from many controlled delivery devices in that release is not controlled solely by diffusion, and the rate of release may therefore be regulated by altering the rate of degradation of the matrix component or the amount of heparin bound within the matrix. The controlled release of such low heparin-binding affinity growth factor proteins such as NGF-&bgr;, NT-3 and BDNF, is demonstrated.

Abstract: Antiobestic agents and health foods containing as the active ingredient substances having an effect of adsorbing bile acid in the digestive tract an effect of inhibiting intestinal circulation or an effect of inhibiting the absorption of exogenous lipids typified by pharmaceutically acceptable anion exchange resins. In particular, antiobestic agents and health foods characterized by lowering body weight and/or visceral fat content without reducing food intake.

Abstract: An agent for promoting excretion of an accumulative chlorine compound comprising a pharmaceutically acceptable anion exchange resin, which is a novel agent that is for promoting the excretion of an accumulative chlorine compound and is capable of efficiently excreting residual chlorinated compounds including dioxins as typical examples.

Abstract: The invention relates to a polystyrene sulfonate-containing gel preparation for therapy of hyperpotassemia, wherein the particle size of polystyrene sulfonate is controlled within the range of at least 5-100 &mgr;m, the viscosity of its solution before gelation is adjusted depending on the particle size by adding a thickening agent, and the polystyrene sulfonate particles after gelation is uniformly dispersed therein. More preferably, a water-displacing agent is contained, whereby the amount of water in the preparation is reduced. This gel preparation does not cause a sense of foreign matter or a sense of roughness in the oral cavity upon ingestion and intake, thus making it unnecessary to drink water for ingestion, and further its water content is low, so that control of water intake is made easy, even in the case of a patient with renal insufficiency who is subjecting to restriction in intake of water to significant improve the quality of life of the patient.

Abstract: The present invention relates to a method for treating air with an iodinated resin to remove contaminants contained in the air. The iodinated resin is an iodinated anion exchange resin. The present invention also relates a system for treating air. The system comprises a means for providing an air path for air to move through, and an iodinated resin disposed in the air path.

Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.

Abstract: In general, a method for removal of pyrogens from plasma or blood according to the present invention comprises: (1) passing the biological fluid through a resin comprising two components: (a) a first component comprising a polymeric support with a multiplicity of ligands comprising a C10-C24 alkylamino group, the ligands specifically binding endotoxin; and (b) a second component comprising a halogenated quinolone moiety immobilized on an amino-group-containing solid support by the formation of an amide linkage, the first component and the second component being present in the resin at a ratio of from about 20:80 (v/v) to about 80:20 (v/v); and (2) collecting the biological fluid from which pyrogens have been removed. Preferably, the alkylamino group is a stearylamino group, and the ligands are cross-linked and quaternized by reaction with a dibromoalkanol. Preferably, the polymeric support of the first component is agarose in particulate form.

Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of −1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.

Abstract: Pharmaceutical dosage units containing flupirtine or a pharmaceutically acceptable salt of flupirtine with controlled release of active substance using a delayed-action or controlled-release component. There are 0.001 to 20 parts delayed-action component for each part by weight flupirtine (calculated as the base) and the release rate of flupirtine is between 5 and 300 mg per hour. In some cases, the dosage units may also contain a rapidly releasing component of flupirtine or of one of its salts. The dosage units reduce the sedative effect of flupirtine.

Abstract: The present invention discloses methods of treating or inhibiting one or more of sick building syndrome (SBS), post-Lyme Disease Syndrome (PLDS), and chronic fatigue syndrome (CFS) by administering to a patient in need thereof an amount effective of cholestyramine and/or &agr;-melanocyte stimulating hormone to treat or inhibit one or more of these syndromes.

Abstract: Novel methods and combinations for the treatment and/or prophylaxis of a pathologic condition in a subject, wherein the methods comprise the administration of one or more aldosterone receptor antagonists and one or more, bile acid sequestering agents and the combinations comprise one or more of said aldosterone receptor antagonists and one or more of said bile acid sequestering agents.

Abstract: The present invention relates to a delivery system for pharmaceutical compositions relying in part on an ionic interaction to control and facilitate release of the treating agent. More specifically, the invention relates to an extended controlled-release system having an ionic treating agent and an ionic polymer, wherein the polymer is sufficiently ionized to release the treating agent in a controlled manner over an extended period of time and the composition does not require an emulsion system for administering the treating agent.

Abstract: Dosage forms are disclosed that reduce or eliminate manufacturing and storage stability problems associated with hygroscopicity and deliquescence.

Abstract: The present invention relates to iodinated resins. It relates in particular to a process for preparing a polyiodide-resin wherein an anion exchange resin is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The absorbable member is selected from the group consisting of I2 and polyiodide ion having a valence of −1. In the process, conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and/or elevated pressure, the elevated temperature being about 100° C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to a substance comprising an iodine (impregnated) resin as produced by the above process.

Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of −1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.

Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of −1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.

Abstract: Solid oral dosage forms of controlled substances are described that have reduced potential for abuse by inhalation, mastication, and injection.

Abstract: A method to assess hypertension by measuring the amount of free and conjugated hydroxyeicosatrienoic acids (DHETs) and metabolites of DHETs, which are metabolites of arachidonic acid (AA) epoxygenases and epoxide hydrolases, in a biological sample which contains the DHETs (using any methods including GC/MS or ELISA) is disclosed. The method further included determining the amount of molecules containing a DHET-specific epitope immunoreactive with antibodies produced against DHETs present in the sample. This amount is compared with a control sample(s). Hypertension is determined through the comparison wherein the amount of increase of free and conjugated DHETs and metabolites of DHETs in the sample isolated from an organism. The present invention also provides a method to assess catalytic activity of AA epoxygenases using immunoassays by subtracting the amounts of NADPH-independent epoxyeicosatriencic acids (EETs) from total (NADPH-dependent+independent) EETs.

Abstract: A method of preventing the growth of heterotrophic bacteria and the subsequent establishment of a biofilm on the surface and in the micropores of an antimicrobial synthetic ion exchange resin. An antimicrobial synthetic ion exchange resin that prevents the growth of heterotrophic bacteria and the subsequent establishment of biofilm on the surface and in the micropores of the resin. A broad spectrum organic antimicrobial agent that is water insoluble and thus precipitates out and becomes encapsulated within micropores of the resin during suspension polymerization. The antimicrobial agent is submicron sized and has a high surface area. The antimicrobial agent protects the antimicrobial synthetic ion exchange bead from the growth of heterotrophic bacteria and the subsequent establishment of biofilm on the surface and in the micropores of the resin. The antimicrobial agent is nontoxic, noncarcinogenic, substantially nonleaching and durable over the lifespan of the bead.

Abstract: A polyion complex (PIC) is formed of an anionic soluble polymer formed from ethylenically unsaturated monomers including at least one anionic or monomer and a cationic soluble polymer formed from ethylenically unsaturated monomer including at least one cationic monomer, in which the monomers used to form at least one of the polymers comprise a zwitterionic monomer and in which the monomers used to form at least one of the polymers include non-ionic monomer, preferably C1-24 alkyl(meth)acrylate, in which the overall ratio of anionic groups to cationic groups in the PIC is in the range 1.5:1 to 1:1.5, and in which the polymers are combined in ratios to provide a PIC in which there are units derived from zwitterionic monomer in an amount in the range 1 to 70 mole % based on total monomer derived units in the PIC and there are units derived from non-ionic monomer in an amount in the range 0 to 60 mole % based on total monomer derived units in the PIC. The PIC is preferably swollen in water and is a flowable gel.

Abstract: A gelled composition was provided by adding a gelling component to a carrier for adsorption. Not only was the taste of the carrier for adsorption significantly reduced in this composition, but the dosage was also decreased so that the composition could be easily taken by a patient.

Abstract: A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4.

Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.

Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.

Abstract: This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene, as the carrier, thereby eliminating the extreme bitterness of the quinolones oral liquid formulation.

Abstract: A method of using ionene polymers for the treatment of mucositis and oral mucositis in mammals is provided. The method comprises administering to a mammal an effective amount of an ionene polymer to prophylactically or therapeutically treat mucositis.

Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.

Abstract: A composition comprising at least one liquid fatty phase structured by at least one semi-crystalline polymer having a low melting point and an organic structure, wherein said polymer is solid at ambient temperature, has a melting temperature of less than 50° C., and comprises a) a polymer backbone and b) at least one crystallizable organic side chain and/or one crystallizable organic block that forms part of the polymer backbone of said polymer, wherein said polymer has a number-average molecular mass of greater than 2 000, and wherein the liquid fatty phase and the polymer form a physiologically acceptable medium. This composition is provided in the form of a stick, for example, which deposits, on keratinous substances such as the lips, a glossy, nonsticky and covering film.

Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.

Abstract: A vitamin K adduct, particularly suitable as vitamin supplement for feeds, constitued by menadione bisulfite bonded with an appropriate ion-exchange resin and exceptionally stabilized thereby. The adduct can be used as an antihemorrhagic additive for farm animal feeds. The high thermal stability of the vitamin adduct allows to use it in modern technologies for producing feeds in extruded form.

Abstract: The present invention relates to pretreating individuals with an effective amount of a flush inhibiting agent for a sufficient period of time prior to the start of single daily dose nicotinic acid therapy to reduce the capacity of nicotinic acid to induce flushing reactions in such individuals during nicotinic acid therapy. In accordance with the present invention, the flush inhibiting agents are administered orally one to four times a day, and preferably one to two times per day, for between about 7 to about 14 days prior to the start of the nicotinic acid therapy. Examples of flush inhibiting agents include nonsteroidal anti-inflammatory agents. Aspirin is a preferred flush inhibiting agent and may be orally administered in daily doses of between about 80 mg to about 1000 mg, and preferably between about 80 mg and about 650 mg, and more preferably between about 80 mg and about 325 mg, during the pretreatment period.

Abstract: A hemostatic agent for arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. One embodiment is directed to a substantially anhydrous admixture of an oxyacid salt and a hydrophilic proton donor which will hydrate in the presence of blood and body fluid to produce cations to promote blood clotting. The preferred oxyacid salts are alkali and alkaline earth salts of transition metals and halogen oxyacids with oxidizing capabilities sufficient to accelerate blood clotting. Another embodiment of the invention includes the compound containing an oxysalt plus a hydrophilic polymer such as carboxy methylcellulose, polyvinyl, alcohol, an alginate, and all soluble gums. Still another embodiment of the invention includes the compound formed of an oxyacid salt in combination with a hydrophilic proton donor and a solid desiccant which further accelerates blood coagulation reaction rates.

Abstract: The invention relates to a method for isolating anionic organic substances from aqueous systems using polymer nanoparticles with cationic pH-sensitive surface groups. Extraction can be carried out directly from diluted solutions, biological media (blood plasma, serum, urine, etc.) and complex buffer systems (e.g. PCR preparations contain detergents) without prior derivatization of the samples or addition of binding buffers. After separation from the surrounding medium the conjugates of the corresponding substances and polymer nanoparticles obtained in this manner can be purified through additional washing steps and effectively desalinated. Owing to the pH-sensitivity of the basic surface groups, the bound substances can be released in a targeted manner after separation by modification of the pH of the medium. By using volatile bases contamination of the released samples with ionic residues can be avoided.

Abstract: A method to assess hypertension by measuring the amount of free and conjugated hydroxyeicosatrienoic acids (DHETS) and metabolites of DHETs, which are metabolites of arachidonic acid (AA) epoxygenases and epoxide hydrolases, in a biological sample which contains the DHETs (using any methods including GC/MS or ELISA) is disclosed. The method further included determining the amount of molecules containing a DHET-specific epitope immunoreactive with antibodies produced against DHETs present in the sample. This amount is compared with a control sample(s). Hypertension is determined through the comparison wherein the amount of increase of free and conjugated DHETs and metabolites of DHETs in the sample isolated from an organism. The present invention also provides a method to assess catalytic activity of AA epoxygenases using immunoassays by measuring the amounts of NADPH-independent epoxyeicosatrienoic acids (EETs) and total (NADPH-dependent+independent) EETs.

Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.

Abstract: The invention relates to a method of removing endotoxin from preparations of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this deprogenation step, and to the depyrogenated product and its clinical uses.

Abstract: A novel hydrophilic ampholytic polymer synthesized by reacting polymerizable amino and carboxy functional ethylenically unsaturated monomers, together with a non-ionic hydrophilic monomer, to provide a polymer having a glass transition temperature (Tg) above about 50° C., and optionally hydrophobic monomer(s), and cross-linking monomer(s). The copolymer is precipitated from a polymerization media which includes a suitable organic solvent. The resulting copolymer is in the form of a fine powder, with submicron particle size. As such it is suitable for use as a thickener or rheology modifier in personal care formulations, such as shampoo, conditioner, and the like, as a bioadhesive, and for other pharmaceutical applications.

Abstract: The present invention relates to polypeptide-polysiloxane copolymers, to their preparation by thermal copolymerization of amino acids with organofunctional polysiloxanes, and to their use as interface-active substances.

Abstract: A highly productive and environmentally friendly method of loading pharmaceutically active substances onto ion exchange resins using water and, if desired, a water miscible or water-immiscible solvent.

Abstract: Broadly defined adhesive latex formula s exhibiting antimicrobial properties. Such formulations comprise certain antimicrobial compounds, such as, preferably, metal-containing ion-exchange and/or zeolite compounds, are provided. The inventive latex formulations must also exhibit substantially uniform characteristics (such a similar viscosity and/or appearance throughout) in order to provide a functionally and aestheticially pleasing formulation for utilization within any number of applications. In order to provide such an inventive latex formulation, it has been found that compounding of all the base ingredients (polymer, antimicrobial agent, fillers) must be undertaken prior to the final thickening step, which ultimately produces the desired latex. The specific method of producing such formulations is also encompassed within this invention.

Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.

Abstract: The present invention relates to a method for preventing or treating skin damage which comprises applying to the skin a composition containing an effective amount of a cosmetically or pharmaceutically acceptable compound capable of acting as an electron donor, simultaneously or substantially simultaneously with the application of a composition containing an effective amount of a cosmetically or pharmaceutically acceptable compound capable of acting as an electron acceptor, whereby an exchange of electrons between the electron donor and electron acceptor results in generation of an electrical current on the skin.

Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.

Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.

Abstract: A cation exchange resin preparation in the dosage form of dry syrups and the like which comprises a cation exchange resin such as polystyrene calcium sulfonate and a gelleing agent such as carboxymethylcellulose sodium (CMC-Na), and may further comprises a binder such as hydroxypropyl cellulose (HPC). The preparation gelates and/or swells without disintegration for a few tens seconds to a minute or so when taken as suspensions in water or the preparation, per se. Therefore, the sandy feel in the mouth and throat, which is a problem in taking the preparation comprising a cation exchange resin alone, is reduced and the taste and easiness in oral administration are both improved.